scholarly journals Evaluation of essential oils from 22 Guatemalan medicinal plants for in vitro activity against cancer and established cell lines

2018 ◽  
Vol 12 (3) ◽  
pp. 42-49 ◽  
Author(s):  
Byron Miller Andrew ◽  
Gordon Cates Rex ◽  
O’Neill Kim ◽  
Alfonso Fuentes Soria Juan ◽  
Vicente Espinoza Luis ◽  
...  
Blood ◽  
1998 ◽  
Vol 92 (10) ◽  
pp. 3804-3816 ◽  
Author(s):  
John C. Byrd ◽  
Charlotte Shinn ◽  
Jamie K. Waselenko ◽  
Ephraim J. Fuchs ◽  
Teresa A. Lehman ◽  
...  

Abstract Flavopiridol has been reported to induce apoptosis in lymphoid cell lines via downregulation of bcl-2. The in vitro activity of flavopiridol against human chronic lymphocytic leukemia (CLL) cells and potential mechanisms of action for inducing cytotoxicity were studied. The in vitro viability of mononuclear cells from CLL patients (n = 11) was reduced by 50% at 4 hours, 24 hours, and 4 days at a flavopiridol concentration of 1.15 μmol/L (95% confidence interval [CI] ±0.31), 0.18 μmol/L (95% CI ±0.04), and 0.16 μmol/L (95% CI ±0.04), respectively. Loss of viability in human CLL cells correlated with early induction of apoptosis. Exposure of CLL cells to 0.18 μmol/L of flavopiridol resulted in both decreased expression of p53 protein and cleavage of the caspase-3 zymogen 32-kD protein with the appearance of its 20-kD subunit. Contrasting observations of others in tumor cell lines, flavopiridol cytotoxicity in CLL cells did not correlate with changes in bcl-2 protein expression alterations. We evaluated flavopiridol’s dependence on intact p53 by exposing splenocytes from wild-type (p53+/+) and p53 null (p53−/−) mice that demonstrated no preferential cytotoxicity as compared with a marked differential with F-ara-a and radiation. Incubation of CLL cells with antiapoptotic cytokine interleukin-4 (IL-4) did not alter the LC50 of flavopiridol, as compared with a marked elevation noted with F-ara-a in the majority of patients tested. These data demonstrate that flavopiridol has significant in vitro activity against human CLL cells through activation of caspase-3, which appears to occur independently of bcl-2 modulation, the presence of IL-4, or p53 status. Such findings strongly support the early introduction of flavopiridol into clinical trials for patients with B-CLL.


2003 ◽  
Vol 15 (4) ◽  
pp. 282-285 ◽  
Author(s):  
Alejandro D. Dellacasa ◽  
Pedro N. Bailac ◽  
Marta I. Ponzi ◽  
Sergio R. Ruffinengo ◽  
Martín J. Eguaras

2016 ◽  
Vol 192 ◽  
pp. 524-534 ◽  
Author(s):  
Francisca Kama-Kama ◽  
Jacob Midiwo ◽  
Joseph Nganga ◽  
Naomi Maina ◽  
Elise Schiek ◽  
...  

Nature ◽  
1974 ◽  
Vol 247 (5441) ◽  
pp. 466-469 ◽  
Author(s):  
P. AMATI ◽  
C. LAGO

2013 ◽  
Vol 34 (1) ◽  
pp. 13-21 ◽  
Author(s):  
Houman Goudarzi ◽  
Yasuhiro Hida ◽  
Hiroko Takano ◽  
Hiroki Teramae ◽  
Hisashi Iizasa ◽  
...  

2016 ◽  
Vol 121 (4) ◽  
pp. 998-1003 ◽  
Author(s):  
J.S. Valente ◽  
A.O.S. Fonseca ◽  
L.B. Denardi ◽  
V.S. Dal Ben ◽  
F.S. Maia Filho ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document